Ziopharm Oncology Downgraded By BMO As 'Questions Persist' By: Benzinga via Benzinga June 22, 2015 at 09:30 AM EDT In a report published Monday, BMO Capital analyst Jim Birchenough downgraded the rating on ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) to ... Read More >> Related Stocks: Ziopharm Oncology IN